Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/S ratio high or low?
The P/S ratio of 934.12 is 17% below its estimated 1-year average of 1130.30, near the low end of its estimated 1-year range (934.12–1302.51).
As of 2026-10-06T22:51:38.728Z.
Calculation as of: 2026-10-06T22:51:38.728Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 88e906b5462319013e69f4ee379284aaffb96e00f9acc248208650345dd3e90c
Current P/S: FMP quote market capitalization / TTM revenue. Historical estimates use price and reported weighted-average shares; daily points use adjusted close × quarterly weighted-average shares / TTM revenue. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
934.12
PS RATIO AVG TTM
N/A
PS RATIO AVG 3Y
N/A
PS RATIO AVG 5Y
N/A
PS RATIO AVG 10Y
N/A
PS RATIO AVG 15Y
N/A
PS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.28
median of 578 covered companies
CURRENT VS SECTOR MEDIAN
+21750.76%
vs the sector median at left
Market Cap
$6.23B
PS Ratio
25.95
TTM Avg
34.19
3Y Avg
32.94
5Y Avg
96.71
Market Cap
$5.95B
PS Ratio
20.48
TTM Avg
18.30
3Y Avg
14.36
5Y Avg
10.80
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.63B | 934.12 | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.66B | 2.57 | 2.49 | 3.22 | 3.36 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.57B | 2.55 | 3.27 | 4.26 | 4.03 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 4.18 | 3.56 | 3.89 | 4.85 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.48B | 2.08 | 1.55 | 1.04 | 0.71 |
| Alkermes plc (ALKS)vs › | $6.99B | 4.19 | 4.02 | 3.38 | 3.54 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.23B | 25.95 | 34.19 | 32.94 | 96.71 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 20.48 | 18.30 | 14.36 | 10.80 |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.31B | 8.37 | 12.09 | 10.57 | 9.17 |
| GRAIL Inc. (GRAL)vs › | $5.89B | 35.65 | 19.95 | 12.77 | 12.77 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q3 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-06 |
| Q4 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-20 |
| Q1 FY2027Period ended 2026-06-30 | $7,095,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $7,095,000 |
Current P/S: $6,627,568,220 market capitalization ÷ $7,095,000 TTM revenue = 934.12x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
At 934.12, P/S is at an extreme level, where the multiple carries little signal — higher than 0% of readings in its estimated 1-year history.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
estimated 1-year low
963.27
median
1137.09
estimated 1-year high
1302.51
P/S Ratio
934.12
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PS RATIO |
|---|---|
| 2026-10-05 | 963.27 |
| 2026-10-02 | 973.99 |
| 2026-10-01 | 974.86 |
| 2026-09-30 | 978.62 |
| 2026-09-29 | 969.35 |
| 2026-09-28 | 970.22 |
| 2026-09-25 | 964.72 |
| 2026-09-24 | 985.00 |
| 2026-09-23 | 1000.64 |
| 2026-09-22 | 1080.31 |
| 2026-09-21 | 1077.12 |
| 2026-09-18 | 1070.46 |
| 2026-09-17 | 1090.74 |
| 2026-09-16 | 1053.95 |
| 2026-09-15 | 1061.77 |
| 2026-09-14 | 1091.03 |
| 2026-09-11 | 1082.34 |
| 2026-09-10 | 1103.77 |
| 2026-09-09 | 1122.61 |
| 2026-09-08 | 1146.36 |
| 2026-09-04 | 1137.09 |
| 2026-09-03 | 1133.32 |
| 2026-09-02 | 1144.04 |
| 2026-09-01 | 1155.92 |
| 2026-08-31 | 1182.57 |
| 2026-08-28 | 1193.58 |
| 2026-08-27 | 1269.49 |
| 2026-08-26 | 1271.51 |
| 2026-08-25 | 1260.21 |
| 2026-08-24 | 1255.00 |
| 2026-08-21 | 1285.42 |
| 2026-08-20 | 1284.84 |
| 2026-08-19 | 1302.51 |
| 2026-08-18 | 1283.39 |
| 2026-08-17 | 1266.30 |
| 2026-08-14 | 1211.54 |
| 2026-08-13 | 1211.54 |
| 2026-08-12 | 1234.14 |
| 2026-08-11 | 1185.76 |
| 2026-08-10 | 1155.63 |
| 2026-08-07 | 1157.37 |